{
    "nctId": "NCT05600582",
    "briefTitle": "A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer",
    "officialTitle": "Phase 1 Study of CodaLytic, an Intratumoral Influenza-based Oncolytic Virus, in Patients With Metastatic or Otherwise Inoperable Breast Cancer",
    "overallStatus": "WITHDRAWN",
    "conditions": "Breast Neoplasms, Neoplasm Metastasis",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 0,
    "primaryOutcomeMeasure": "To assess the Serious Adverse events (SAEs) of CodaLytic administered by intratumoral injection",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women or men with metastatic or inoperable, histologically confirmed breast cancer\n* Has no alternative treatment of proven benefit available or has refused treatment\n* Expected survival \u2265 3 months\n* At least 2 measurable lesions according to RECIST 1.1, without contraindication for repeated injections and core needle biopsies\n* Adequate organ function\n* Eastern Cooperative Oncology Group performance status of 0 to 2\n* Negative pregnancy test, if female\n* Agreement to practice a highly effective method of contraception\n* Agreement to no sperm donation through 28 days, if male\n* Willing to provide consent to perform study procedures\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Anticancer therapy within 3 weeks of dosing\n* Known active central nervous system metastases (with some exceptions)\n* Presence of a concurrent malignancy for which the natural history or treatment has the potential to interfere with the safety or efficacy assessment of the Investigational Product\n* Uncontrolled or severe cardiovascular disease\n* Immunodeficiency or use of therapies expected to impair the immune response within thirty (30) days of enrollment or during dosing.\n* Ongoing toxicity \\> Grade 1 from prior treatment except those which are stable\n* History of severe reaction (ie, anaphylaxis) to vaccination or immunotherapy\n* Planned radiation to lesions targeted for assessment/injection within 60 days before first dose or any planned radiation during dosing period\n* Any condition or occupational or other responsibility that in the judgment of the Investigator would interfere with or serve as a contraindication to protocol adherence, assessment of safety, or a participant's ability to give informed consent",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}